NCT02244541View on ClinicalTrials.gov

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

ANAVEX2-73 Oral

DRUG

ANAVEX2-73 Intravenous

DRUG

ANAVEX2-73 Oral

30 mg hard gelatin capsule

DRUG

ANAVEX2-73 Oral

50 mg hard gelatin capsule

Trial Locations (5)

3050

Melbourne Health - The Royal Melbourne Hospital, Melbourne

3084

Austin Health - Heidelberg Repatriation Hospital, Melbourne

3162

Caulfield Hospital, Melbourne

Unknown

Nucleus Network- Centre for Clinical Studies, Melbourne

St. Vincent's Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Anavex Life Sciences Corp.

INDUSTRY